<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Scant information is available concerning the occurrence and evolution of chemotherapy-induced acral <z:hpo ids='HP_0010783'>erythema</z:hpo> in children receiving intravenous high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) </plain></SENT>
<SENT sid="1" pm="."><plain>Among 50 children with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> or lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> receiving a total of 203 courses of high-dose MTX (3-8 g/m2), 3 cases of acral <z:hpo ids='HP_0010783'>erythema</z:hpo> were observed </plain></SENT>
<SENT sid="2" pm="."><plain>Painful <z:hpo ids='HP_0010783'>erythema</z:hpo> of finger and toe pads was noted in three children 3 days to 2 weeks after MTX infusion </plain></SENT>
<SENT sid="3" pm="."><plain>The lesions resolved completely after <z:mp ids='MP_0001208'>blister</z:mp> formation and desquamation </plain></SENT>
<SENT sid="4" pm="."><plain>These patients subsequently received high-dose MTX therapy without cutaneous problems </plain></SENT>
<SENT sid="5" pm="."><plain>The present work points out that the chemotherapeutic schedule need not be modified in selected patients who develop acral <z:hpo ids='HP_0010783'>erythema</z:hpo> following high-dose MTX infusion </plain></SENT>
</text></document>